SLC5A2 and type 2 diabetes mellitus: New drugs for treatment of type 2 diabetes mellitus (T2DM) have proliferated over the past 15 years, with the introduction of glucagon‐like peptide 1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose transport protein 2 (SGLT‐2 inhibitors).1, 2, 3, 4